United States & Lupin (company)

United States: The U.S. is where YUVEZZI has received FDA approval and where Tenpoint is preparing for commercial launch, serving as a reference market for the product.

Lupin (company): Lupin, through its subsidiary VISUfarma, secures exclusive rights to commercialize YUVEZZI in key European Union — European markets, strengthening its ophthalmology franchise and specialty care strategy. The deal includes a strategic investment and potential milestone payments, which could enhance future revenue.

United States: The US is imposing tariffs to boost domestic manufacturing, which may reduce reliance on imports but could increase drug costs.

Lupin (company): Lupin is a major generic drug supplier to the US; the tariff plan poses a risk to its US market share.

United States: The recall affects U.S. patients and the FDA's regulatory environment; no direct economic impact on the country.

Lupin (company): Lupin (company) is the manufacturer of the recalled eye drops; the recall may harm its brand and lead to potential liability, though the company is cooperating voluntarily.

United States: The United States market is where the newly approved Eribulin Mesylate Injection will be sold, impacting healthcare access and affordability for patients in the country.

Lupin (company): Lupin (company), in partnership with Natco Pharma, received U.S. FDA approval for Eribulin Mesylate Injection, which is expected to provide a competitive edge in the oncology market and contribute to its sales.

United States: The US approved Awiqli earlier in 2026, contributing to its global rollout.

Lupin (company): Lupin's insulin glargine products face increased competition from Awiqli.

United States: Kaveri is based in the U.S., where clinical trials will be conducted.

Lupin (company): Lupin spins out two oncology assets to Kaveri, retaining significant equity and providing seed funding, which may streamline its pipeline and create value.